Notice of Intent to Sole Source - Lateral flow assay design using antibodies developed by the CDC to detect antiretroviral drugs

NOTICE OF INTENT TO ISSUE AN ORDER.  This is not a request for competitive proposals/quotes. The Centers for Disease Control and Prevention (CDC) hereby announces its intent to issue a sole source order to NanoComposix, Inc. 4878 Ronson Ct., Suite J San Diego, CA for of the procurement of  Nanocomposix Lateral flow assay design using antibodies developed by the CDC to detect antiretroviral drugs

The NAICS code for this acquisition is 541713 Research And Development In Nanotechnology

*****

Subject to the Availability of Funds

*****

Nanocomposix Lateral flow assay design using antibodies developed by the CDC to detect antiretroviral drugs

*****

A determination by the Government not to compete this proposed action will be based on responses to this notice and is solely in the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

All vendors must be registered in the System for Award Management (SAM) at www.sam.gov , prior to an award of a federal contract.

This action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit quotations.

This is not a request for competitive quotations; however, the Government will review any/all product, capabilities, and pricing information submitted prior to the closure of this notice. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

Responsible sources that believe they possess the expertise and capabilities identified above are hereby afforded the opportunity to submit to the Contracting Officer by the due date of this notice, their written capabilities statement and pricing information in the format they choose, not to exceed 10 pages. Please forward, as applicable, any capabilities, product, pricing information (for products, etc.), and/or other pertinent information to kpz6@cdc.gov.

Any responses should be emailed to kpz6@cdc.gov by April 26, 2024 at 12:00 PM. EST.